This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site



Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyOff-contract claimsAlliance Healthcare

Example content



AMSAMSAn introduction to antimicrobial stewardshipStewardshipSurveillanceRace against resistanceABSABSABS in practice Educational ResourcesAFSAFSShape the futureAFS in practiceImplementing an AFS programmeDiagnosticsGuidelinesCase studiesAll case studiesOur CommitmentOur CommitmentOur commitment to anti-infectivesHeritageSustainability
Our work in the community
Support & ResourcesSupport & ResourcesVideosMaterialsOnline LearningOnline LearningHomeINSPIRE To: Change the CourseLondon AMS SeriesNorth West England AMS SeriesInfectious Thinking Podcasts

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

StewardshipPfizer leads across stewardship metrics and is ranked among top two large R&D pharmaceutical companies in the fight against antimicrobial resistance (AMR)1The 2020 AMR Benchmark highlighted key areas of our leadership, including:
Scroll left to view table
Stewardship Metrics Pfizer is ranked first across stewardship metrics. Through a pilot established in 2019, Pfizer fully decoupled sales bonuses from volumes for antibacterial and antifungal medicines in the UK and partially decoupled bonuses from sales volumes in other countries. Pfizer was also recognized as the first company to share raw data on resistance collected via our open-access ATLAS surveillance program.1
Continuous Supply Pfizer is a leading company when it comes to filing relevant on-patented products for registration in low- and middle-income countries and taking steps to ensure continuous supply.1
Active in R&D Pfizer is one of the few large research-based pharmaceutical companies still active in R&D for antibacterial medicines and vaccines.1
alt="Risk management strategy " Pfizer has a comprehensive environmental risk-management strategy for our manufacturing sites, and those of our suppliers, to limit AMR.1
Educational Resources

We have a variety of educational resources aimed at supporting Healthcare Professsionals looking to enhance their knowledge of AMR and Stewardship.

Access resources Loading
*The Access to Medicine Foundation AMR Report

The Access to Medicine Foundation published its 2020 Antimicrobial Resistance Benchmark in February 2020. The bi-yearly report evaluates our industry’s progress in the fight against antimicrobial resistance (AMR). The Foundation's Benchmark provides an independent comparison of 30 pharmaceutical research companies' efforts to curb AMR across three research areas: research and development, manufacturing and production, and appropriate access and stewardship.

Download ReportLoading
About Access to Medicine Foundation

The Access to Medicine Foundation is an independent non-profit organization based in the Netherlands. It aims to advance access to medicine in low- and middle-income countries by stimulating and guiding the pharmaceutical industry to play a greater role in improving access to medicine.1

Educational Resources Visit our AMS Online Learning Platform Stay up to date with our online modules comprised of short videos, learning objectives, questions & online learning certificates. Online LearningLoadingBritish Society for Antimicrobial Chemotherapy (BSAC) Antimicrobial Stewardship Massive Open Online Courses (MOOC)

We are proud to sponsor a collaboration with the British Society for Antimicrobial Chemotherapy and the University of Dundee on the development of an online educational course for healthcare professionals on antibiotic stewardship.2 Pfizer were the main consortium sponsor for the BSAC Antimicrobial Stewardship (AMS) MOOC when it launched in 2015, over 53,500 participants have enrolled for the AMS MOOC from over 200 countries. In addition, the AMS MOOC has been translated into a number of languages including Russian, Chinese and Portuguese. The AMS MOOC is just one of the BSAC educational programmes that Pfizer have sponsored. 

Antimicrobial Susceptibility Testing (AST)

Launched in 2017, the Pfizer UK Antibiotic Susceptibility Testing (AST) programme provides NHS Trusts access to AST diagnostics in order to ensure responsible prescribing and support appropriate stewardship of our anti-infectives. The AST programme allows clinicians to inform their patient therapy decisions using commercially available AST diagnostic tests, and therefore to prescribe antibiotics appropriately. This will also help to protect the useful life of the antibiotic (from antibiotic resistance) by ensuring hospitals can exert appropriate stewardship. 

If you would like to speak with one of the Pfizer team about how we can provide additional support, please contact us here to request a call back or email.

Antimicrobial Stewardship Toolkit

The AMS Toolkit contains a variety of resources aimed to offer tips and advice to HCPs looking to implement and maintain an AMS programme within the secondary healthcare setting. To access and download these resources, please click here.​

AMS Lead Resource Pack - 'At a Glance'

Leading an AMS programme is a multi-faceted process requiring a coordinated response that engages colleagues and supports their active involvement. The items within this pack are designed to help you and your AMS Champions deliver excellent and consistent patient care through collaboration between all members of the hospital team.

AMS Champion Resource Pack - 'At a Glance'

As an AMS Champion you play a key role in engaging with colleagues and supporting their active involvement with Antimicrobial Stewardship. The items within this pack are designed to help AMS Champions develop excellent and consistent patient care through collaboration with all members of the hospital team.


Prescribing Information

Click here for Prescribing Information for Cresemba (isavuconazole), Zavicefta (ceftazidime-avibactam) and Zinforo (ceftaroline fosamil)


Access to Medicine Foundation. Antimicrobial resistance benchmark 2021. Available at: Antimicrobial Resistance Benchmark - A research programme by the Access to Medicine Foundation [Last accessed October 2022]British Society for Antimicrobial Chemotherapy. Acknowledgements. Available at: [Last Accessed October 2022]
PP-UNP-GBR-2386. October 2022.

Adverse events should be reported. Reporting forms and information can be found at or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2023 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-UNP-GBR-4885. May 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
You are now leaving PfizerPro
​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021